Effects of Daflon 500mg on postischemic macromolecular leak syndrome in striated skin muscle of the hamster.
We have recently shown that the purified micronized flavonoid fraction (90% diosmin and 10% hesperidin) Daflon 500 mg attenuates reperfusion injury in the striated skin muscle of the hamster. Herein, we report on the action of Daflon 500 mg on postischemic macromolecular leakage of FITC-dextran 150 kD provoked by tourniquet ischemia. Intravital fluorescence microscopy was used for analysis of macromolecular leakage in the microcirculation model of the hamster. A tourniquet ischemia of 4 h duration was induced followed by reperfusion. Animals were treated by gavage of Daflon 500 mg (n = 6) for 8 days at a daily dose of 30 mg kg(-1) body weight. Control animals received equivalent volumes of the vehicle (5% Arabic gum solution, n = 6). Measurements of the microcirculatory parameters were made before induction of ischemia and at 0.5, 2 and 24 h of reperfusion. After induction of ischemia, macromolecular leakage from postcapillary venules was significantly enhanced in vehicle-treated animals. Treatment with Daflon 500 mg significantly attenuated macromolecular leakage of FITC-dextran 150 kD. Preliminary data from a histomorphometric analysis (n = 3/experimental group) indicated that the number of emigrated (extravascular) leukocytes after ischemia reperfusion was markedly reduced in Daflon 500 mg-treated animals as compared to controls. These data indicate that Daflon 500 mg prevents leakage of the macromolecular tracer FITC-dextran 150 kD from postcapillary venules after postischemic reperfusion, presumably through an inhibitory action on the emigration of activated leukocytes.
Nolte
D
D
Institute for Surgical Research, Klinikum Grosshadern, University of Munich, Germany. nolte@icf.med.uni-muenchen.de
Pickelman
S
S
Schütze
E
E
Möllmann
M
M
Messmer
K
K
D000818:Animals; D019559:Capillary Leak Syndrome / Q000188:drug therapy*; D006224:Cricetinae; D003911:Dextrans / Q000097:blood / Q000378:metabolism; D004145:Diosmin / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005119:Extravasation of Diagnostic and Therapeutic Materials; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives / Q000378:metabolism; D007511:Ischemia / Q000188:drug therapy*; D008647:Mesocricetus; D018482:Muscle, Skeletal / Q000098:blood supply / Q000187:drug effects*; D015427:Reperfusion Injury / Q000188:drug therapy*; D012867:Skin / Q000098:blood supply*; D014111:Tourniquets
D003911:Dextrans; C015219:fluorescein isothiocyanate dextran; D004145:Diosmin; D016650:Fluorescein-5-isothiocyanate